SBH
EVH icon

Segall Bryant & Hamill’s Evolent Health EVH Stock Holding History

Segall Bryant & Hamill’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-320,454
Closed -$8.87M – 753
2021
Q4 		$8.87M Buy
320,454
+13,483
+4% +$387K 0.08% 220
2021
Q3 		$9.51M Sell
306,971
-302,714
-50% -$7.27M 0.09% 223
2021
Q2 		$12.9M Sell
609,685
-362
-0.1% -$7.25K 0.12% 185
2021
Q1 		$12.3M Buy
610,047
+181,791
+42% +$3.46M 0.12% 190
2020
Q4 		$6.86M Buy
+428,256
New +$5.66M 0.08% 239
2019
Q1 		– Sell
-34,536
Closed -$689K – 834
2018
Q4 		$689K Buy
34,536
+57
+0.2% +$1.32K 0.01% 587
2018
Q3 		$979K Buy
+34,479
New +$822K 0.01% 550

Other funds holding EVH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Segall Bryant & Hamill's EVH Position: Q1 2022 in Review

Segall Bryant & Hamill sold out of Evolent Health (EVH) in Q1 2022, closing a stake of 320,454 shares — an estimated $8.87M sold.

Segall Bryant & Hamill first reported a position in EVH in Q3 2018 and held it in 7 quarters. The position peaked at $12.9M in Q2 2021. 218 funds tracked by Wall St. Rank hold EVH as of Q1 2022.

  • Segall Bryant & Hamill reported no remaining Evolent Health position as of Q1 2022 after selling out during the quarter.
  • Segall Bryant & Hamill sold 320,454 Evolent Health shares in Q1 2022, an estimated $8.87M.
  • Segall Bryant & Hamill first reported a position in Evolent Health in Q3 2018 and held it in 7 quarters.
  • Segall Bryant & Hamill's Evolent Health position peaked at $12.9M in Q2 2021.
  • 218 funds tracked by Wall St. Rank held Evolent Health as of Q1 2022.

Based on Segall Bryant & Hamill's 13F filing for Q1 2022, filed 13 May 2022.